ArticleInternational urology and nephrology2026
Therapeutic outcomes and predictive factors of intradetrusor onabotulinumtoxinA for neurogenic detrusor overactivity (NDO) associated with spinal cord lesion.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeIntradetrusor onabotulinumtoxinA (Botox) is an established treatment for neurogenic detrusor overactivity (NDO), although predictors of success remain unclear. This study evaluated the therapeutic efficacy of Botox and identified predictors of response in patients with spinal cord lesion (SCL)-related NDO.
methodsWe retrospectively reviewed 167 patients with SCL-related NDO who received intradetrusor 200 U Botox at a single center between January 1, 2002, and December 31, 2024. Treatment response was classified using the Global Response Assessment (GRA) as excellent (GRA = 3), moderately improved (GRA = 2), mildly improved (GRA = 1), or no change (GRA = 0). Success was defined as GRA = 3 or 2. Baseline demographics, neurological level, and videourodynamic (VUDS) parameters, including detrusor pressure at maximum flow (Pdet), maximum flow rate, voided volume, post-void residual, voiding efficiency (VE), bladder outlet obstruction index (BOOI), and bladder contractility index (BCI), were analyzed as predictors.
resultsVUDS confirmed detrusor overactivity in 92.8%. Overall, 51.5% (86/167) achieved an excellent response, 43.1% (72/167) improved, and 5.4% (9/167) showed no change. Outcomes did not differ by neurological level (P = 0.665). Patients with successful outcomes had higher baseline P
conclusionsIntradetrusor Botox produced good efficacy in SCL-related NDO. Higher baseline detrusor pressure, bladder contractility, and bladder outlet resistance predicted better outcomes, whereas greater VE was associated with nonresponse. Neurological level did not influence treatment success.
Indexed as
Identifiers
41385039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.